Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study

Author： Carlquist John   Horne Benjamin   Muhlestein Joseph   Lappé Donald   Whiting Bryant   Kolek Matthew   Clarke Jessica   James Brent   Anderson Jeffrey  

Publisher： Springer Publishing Company

ISSN： 0929-5305

Source： Journal of Thrombosis and Thrombolysis, Vol.22, Iss.3, 2006-12, pp. : 191-197

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cytochrome P450 1B1 and 2C9 Genotypes and Risk of Ischemic Vascular Disease, Cancer, and Chronic Obstructive Pulmonary Disease

By  

Current Vascular Pharmacology, Vol. 10, Iss. 4, 2012-01 ,pp. : 512-520

Bentham Science Publishers

Access to resources Recommend Favorite

Maintenance warfarin dose varies according to two haplotypes of the vitamin K epoxide reductase gene

By John Jerry M   Herrington David M  

Future Cardiology, Vol. 2, Iss. 1, 2006-01 ,pp. : 29-32

Future Medicine

Access to resources Recommend Favorite

Vitamin K 2,3-epoxide reductase and the vitamin K-dependent -carboxylation system

By Wallin R.   Sane D.C.   Hutson S.M.  

Thrombosis Research, Vol. 108, Iss. 4, 2002-11 ,pp. : 221-226

Elsevier

Access to resources Recommend Favorite

Warfarin Analog Inhibition of Human CYP2C9-Catalyzed S-Warfarin 7-Hydroxylation

By Zhang Z.-Y.   Kerr J.   Wexler R.S.   Li H.-y.   Robinson A.J.   Harlow P.P.   Kaminsky L.S.  

Thrombosis Research, Vol. 88, Iss. 4, 1997-11 ,pp. : 389-398

Elsevier

Access to resources Recommend Favorite

Cytochrome P450 2C is an EDHF Synthase in Coronary Arteries

By Fleming I.  

Trends in Cardiovascular Medicine, Vol. 10, Iss. 4, 2000-05 ,pp. : 166-170

Elsevier

Access to resources Recommend Favorite